Alzheimer’s disease (AD) is progressive, irreversible, neurodegenerative memory disorder linked with somehow aging and comes under the umbrella of dementia. It may be rare Familial AD or randomly occurring Sporadic AD. Some preventable acquired risk factors and non-preventable e.g., age and genetics are the main risk factors for Alzheimer’s. The most essential genetic risks factor for (LOAD) late onset of Alzheimer’s disease is APOE genes present on chromosome 19, has three major alleles (e2, e3, and e4). We can slow Alzheimer’s but cannot prevent or stop it till now. Some non-drug treatments, like physical activity, social engagement, nutritious supplemented food, and FDA approved drugs i.e., Donepezil, Galantamine, cholinesterase inhibitors, Mementine, Antidepressants, Antipsychotics and mood stabilizing medication helps to reduce AD.

Keywords: Amyloid beta (AB), Apolipoprotein (APO), Tangle formation, Cerebrovascular (CBV), Late onset of Alzheimer’s disease (LOAD), APOE isoforms, Ligand activated receptors (LXRs).

[1] R. J. Castellani, R. K. Rolston, and M. A. Smith, (2010). Alzheimer disease, Disease-a-Month, 56(9): 484-546.

[2] Huynh T V, Davis AA, Ulrich JD, Holtzman DM. (2017). Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid and other amyloidogenic proteins. J Lipid Res., 58(5): 824-836.

[3] Ward A, Crean S, Mercaldi CJ, et al. (2012). Prevalence of Apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with alzheimer’s disease: A systematic review and meta-analysis, Neuroepidemiology, 38(1): 1-17.

[4] El M, Antoine P, Amouyel P, Lambert J, Pasquier F, Kapogiannis D. (2016). Apolipoprotein E (APOE) 4 and episodic memory decline in Alzheimer ’ s disease: A review. Ageing Res Rev., 27: 15-22.

[5] A. Guarino, F. Favieri, I. Boncompagni, F. Agostini, M. Cantone, and M. Casagrande, (2019). Executive functions in Alzheimer disease: A systematic review, Front. Aging Neurosci., 10.

[6] A.L. Calderon-Garcidueñas and C. Duyckaerts, (2018). Alzheimer disease, Handb. Clin. Neurol., 145: 325-337.

[7] J. Povova et al. (2012). Epidemiological of and risk factors for Alzheimer’s disease: A review, Biomed. Pap., 156(2): 108-114.

[8] F. Massoud and G. C. Léger, (2011). Pharmacological treatment of Alzheimer disease, Can. J. Psychiatry, 56(10): 579-588.

[9] G. Leonenko et al. (2021). Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores, Nat. Commun., 12(1).

[10] D. P. Wightman et al., (2021). A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease, Nat. Genet., 53(9): 1276-1282.

[11] C. Shah, M. A. A. DeMichele-Sweet, and R. A. Sweet, (2017). Genetics of psychosis of Alzheimer disease, Am. J. Med. Genet. Part B Neuropsychiatric. Genet., 174(1): 27-35.

[12] R. Sims, M. Hill, and J. Williams, (2020). The multiplex model of the genetics of Alzheimer’s disease, Nat. Neurosci., 23(3): 311-322.

[13] H. Braak, D. R. Thal, E. Ghebremedhin, and K. Del Tredici, (2011). Stages of the Pathologic Process in Alzheimer Disease: Age Categories from 1 to 100 Years, 70(11): 960-969.

[14] T. Wyss-Coray and J. Rogers, (2012). Inflammation in Alzheimer disease-A brief review of the basic science and clinical literature, Cold Spring Harb. Perspect. Med., 2(1): 1-24.

[15] Alzheimer Association, (2015). Basics of Alzheimer ’ S Disease,” Alzheimer’s Assoc. Rep.

[16] Y. N. Ou et al. (2021). Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood, Mol. Psychiatry, 1-9.

[17] S. S. S. Hernández et al. (2015). What are the benefits of exercise for Alzheimer’s disease? A systematic review of the past 10 years, J. Aging Phys. Act., 23(4): 659-668.

[18] B. Duthey, (2013). Background Paper 6.11 Alzheimer Disease and other Dementias, Update on 2004, World Heal. Organ., 1-77.

[19] J. Povova et al. (2012). Epidemiological of and risk factors for Alzheimer’s disease: A review, Biomed. Pap., 156(2): 108-114.

[20] F. Massoud and G. C. Léger, (2011). Pharmacological treatment of Alzheimer disease, Can. J. Psychiatry, 56(10): 579-588.

[21] G. Leonenko et al. (2021). Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores, Nat. Commun., 12(1).